Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376526 · ClinicalTrials.gov registry record · Phase 2
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Dickran Kazandjian, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06376526 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Dickran Kazandjian, MD. The registered enrollment target is 28 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06376526, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Dickran Kazandjian, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition.
Conditions Studied
Interventions
- BIOLOGICAL Linvoseltamab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376526
The ClinicalTrials.gov registry entry for NCT06376526 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Dickran Kazandjian, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Linvoseltamab is the first listed.
NCT06376526 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06376526 about?
NCT06376526 is a clinical study titled "IMMUNOPLANT for Newly Diagnosed Multiple Myeloma". The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also...
What is the current status of trial NCT06376526?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-08-21. Estimated completion is 2029-08-31.
What conditions does trial NCT06376526 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06376526?
The interventions under investigation include: Linvoseltamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06376526?
This trial is sponsored by Dickran Kazandjian, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376526 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
-
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.